alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 37 studies with an author at University of Alberta (CA) (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA neurology 2020-05-01

Outpatient PC is associated with benefits among patients with PDRD compared with standard care alone. 5 key findings →

Participants: 584 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment: Results From the Gait and Brain Study

✓ Peer-reviewed alzhub usefulness score 68 out of 100. JAMA neurology 2017-07-01

Among 112 study participants with MCI, mean (SD) age was 76.6 (6.9) years, 55 were women (49.1%), and 27 progressed to dementia (24.1%), with an incidence rate of 121 per 1000 person-years. 3 key findings →

Design: cohort study Participants: 112 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Parkinsonism & related disorders 2020-07-11

These findings have implications for clinical practice and suggest that presence of a caregiver may be an important modifying variable on patient outcomes to examine in future research. 3 key findings →

Design: randomized controlled trial Participants: 210 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A Comparison of Users and Nonusers of a Web-Based Intervention for Carers of Older Persons With Alzheimer Disease and Related Dementias: Mixed Methods Secondary Analysis

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of medical Internet research 2019-10-17

At baseline, there were no statistically significant differences in demographic characteristics and in outcome variables (HHI, GSES, and SF-12v2 mental component score and physical component score) between users and nonusers. 5 key findings →

Design: randomized controlled trial Participants: 101 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Study protocol: pragmatic randomized control trial of an internet-based intervention (My tools 4 care) for family carers

✓ Peer-reviewed alzhub usefulness score 58 out of 100. BMC geriatrics 2017-08-14

Data collection began in Ontario and Alberta Canada in June 2015 and is expected to be completed in June 2017. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 58 out of 100. JAMA neurology 2025-06-30

Mean (SD) β-glucocerebrosidase levels were higher at week 26 (ambroxol, 12.45 [1.97] nmol/h/mg; 91% CI, 11.54-13.36 nmol/h/mg); placebo, 8.50 [1.96] nmol/h/mg; 91% CI, 7.65-9.34 nmol/h/mg; P = .05) in the ambroxol group compared with placebo. 3 key findings →

Design: clinical trial Participants: 75 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A Web-Based Intervention to Help Caregivers of Older Adults With Dementia and Multiple Chronic Conditions: Qualitative Study

✓ Peer-reviewed alzhub usefulness score 56 out of 100. JMIR aging 2018-04-23

Recent evidence suggests that Web-based interventions have the potential to support caregivers by decreasing caregiver stress and burden. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Preventing dementia by preventing stroke: The Berlin Manifesto

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2019-07-01

The incidence of stroke and dementia are diverging across the world, rising for those in low- and middle-income countries and falling in those in high-income countries. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Signals in Host-Microbe Interplay

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nutrients 2021-01-14

Intimate metabolic host-microbiome crosstalk regulates immune, metabolic, and neuronal response in health and disease, yet remains untapped for biomarkers or intervention for disease. 2 key findings →

Participants: 77 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-07-29

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Study protocol: pragmatic randomized control trial of my tools 4 care- in care (MT4C-in care) a web-based tool for family Carers of persons with dementia residing in long term care

✓ Peer-reviewed alzhub usefulness score 52 out of 100. BMC geriatrics 2020-08-10

Data collection will begin in four Canadian provinces (Alberta, Manitoba, Ontario and Saskatchewan) in February 2020 and is expected to be completed in June 2021. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Factors associated with rushed and missed resident care in western Canadian nursing homes: a cross-sectional survey of health care aides

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of clinical nursing 2015-07-16

Health care aides frequently report care that is rushed and tasks omitted due to lack of time. 4 key findings →

Design: cross-sectional Participants: 583 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neuron 2024-09-30

The strongest risk factors for late-onset sporadic Alzheimer's disease (AD) include the ε4 allele of apolipoprotein E (APOE), the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2), and female sex. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. npj Parkinson s Disease 2025-03-21

This narrative review examines the utility of gait digital biomarkers in Parkinson's disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. 1 key finding →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed